Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer | NEJM
In an early-phase study involving patients with advanced non–small-cell lung cancer (NSCLC), the response rate was better with nivolumab plus ipilimumab than with nivolumab monotherapy, particularl...
nejm.org